On Charlottesville and Trump

CONTINUING THE MARCH TOWARD SOCIAL JUSTICE SUPPORTS OUR MISSION TO END HIV AND HEPATITIS C The HIV and hepatitis C epidemics disproportionately affect the most marginalized communities of people in American society. Factors that define who we are, and especially how society sees us – the…Read More

PleasePrEPMe.org and Project Inform launch new PrEP navigation manual in California

PleasePrEPMe.org and Project Inform are pleased to announce a free new resource to assist PrEP navigation staff in California: “Helping People Access PrEP: A Frontline Provider Manual on PrEP Research, Care and Navigation.” This publication provides a wide range of information to aid the daily work…Read More

Will the Right Approach to the US Opioid Emergency Prevail?

by Emalie Huriaux The United States is in the midst of a devastating epidemic of opioid use affecting people of widely varying racial, gender and economic groups and status. President Trump responded to this emergency by creating a White House Opioid Commission, headed by Governor Chris…Read More

United Healthcare discriminates against vulnerable populations by denying PrEP access

Project Inform joined many other partners including the AIDS Foundation of Chicago to demand United Healthcare halt their practices and policies that discriminate against the LGBTQ community. Earlier this year, United Health Care began to send members letters denying access to Truvada prescribed for Pre-Exposure Prophylaxis or…Read More

Epclusa receives FDA approval for treating HCV in HIV/HCV co-infected persons

On August 1, 2017 the Food and Drug Administration (FDA) updated the approval for the Gilead HCV medication sofosbuvir/velpatasvir (400mg/100mg), brand name “Epclusa” to include HIV/HCV coinfection. This single tablet medication comprises sofosbuvir (SOF), a nucleotide polymerase inhibitor, and velpatasvir (VEL), an NS5A inhibitor, and is…Read More

July 28 is World Hepatitis Day: Eliminate Hepatitis

July 28, 2017 is World Hepatitis Day, one of only four disease-specific days recognized by the World Health Organization. Around the world and around the United States organizations and individuals come together on this day to raise awareness of the global burden of viral hepatitis and…Read More

Vosevi: Frequently Asked Questions

On July 18, 2017 the Food and Drug Administration (FDA) approved Gilead’s HCV medication sofosbuvir/velpatasvir/voxilaprevir (400mg/100mg/100mg), brand name “Vosevi” for the re-treatment of HCV in treatment-experienced people. This single tablet medication comprises sofosbuvir (SOF), a nucleotide polymerase inhibitor, velpatasvir (VEL), an NS5A inhibitor, and voxilaprevir (VOX),…Read More